Aleman et al., 2021, USA, Prospective cohort |
Dose 2: |
MM |
Mean [range]: 65 [47–79], 63% |
BNT162b2, mRNA-1273 |
28D or 21D |
Second Dose |
Healthy participants (n = 12), Mean [range]: 59 [45–64], 50% |
12 |
≥3.2 AU/mL |
7 |
Patients (n = 44) |
(n = 12) |
Seronegative (n = 27) |
S.R-100% |
Seropositive (n = 17) |
|
S.R-39% |
|
Avivi et al., 2021, Israel, Prospective cohort |
Dose 2: |
MM, SM |
Median [range]: 70 [38–94], 56% |
BNT162b2, mRNA-1273 |
21D |
Second Dose |
Median [range]: 67 [41–84], 42.2% |
63 |
≥0.8 IU/mL |
7 |
Patients (n = 171) |
(n = 64) |
Seronegative (n = 38) |
S.R-98% |
Seropositive (n = 133) |
S.R-78% |
Bergman et al., 2021, Sweden, Prospective cohort |
Dose 2: |
CLL |
NA |
BNT162b2, mRNA-1273 |
21D |
Second Dose |
NA |
69 |
≥0.8 U/mL |
9 |
Patients (n = 388) |
(n = 2) |
Seronegative (n = 108) |
S.R-95.8% |
Seropositive (n = 280) |
|
S.R-72% |
|
Bitoun et al., 2021, France, Retrospective cohort |
Dose 2: |
MM |
Median [range]: 71 [46–93], 44% |
BNT162b2, mRNA-1273 |
28D |
Second Dose |
Median [range]: 58 [26–88], 28.6% |
26 |
≥0.4 IU/mL |
5 |
Patients (n = 27) |
(n = 28) |
Seronegative (n = 3) |
S.R-96% |
Seropositive (n = 24) |
S.R-89% |
|
Canti et al., 2021, Belgium, Prospective cohort |
Dose 2: |
alloHCT |
Median [range]: 60 [26–76], 47.5% |
BNT162b2, mRNA-1273 |
21D |
Second Dose |
Median [range]: 48 [23–64], 27.5% |
40 |
≥5 IU/mL |
8 |
Patients (n = 37) |
S.R-88% |
Seronegative (n = 5) |
|
Seropositive (n = 32) |
|
S.R-86% |
|
Chowdhury et al., 2021, UK, Retrospective cohort |
Dose 1: |
CML, ET, PV, MF, MDS |
Median [IQR]: 62 [52–73], 45.8% |
BNT162b2, AZD1222 |
2 W |
First Dose |
Median [range]: 62 [60–76] |
224 |
≥50 AU/mL |
6 |
Patients (n = 59) |
(n = 232) |
Seronegative (n = 25) |
S.R-97% |
Seropositive (n = 34) |
|
S.R-58% |
|
Chung et al., 2021, USA, Prospective cohort |
Dose 1: |
leukemia, lymphoma, MM |
Median [range]: 65 [22–97], 56.4% |
BNT162b2, mRNA-1273 |
28D or 21D |
First Dose and Second Dose |
Median [range]: 31 [22–67] |
First Dose: 59 |
Immunoassay ≥50.0 AU/mL |
6 |
Patients (n = 167) |
(n = 59) |
Seronegative (n = 81) |
S.R-100% |
Seropositive (n = 86) |
Second Dose: 54 |
|
(n = 54) |
Dose 2: |
S.R-100% |
Patients (n = 456) |
|
Seronegative (n = 142) |
|
Seropositive (n = 314) |
|
S.R-51% & 69% |
|
Crombie et al., 2021, USA, Prospective cohort |
Dose 1: |
Lymphoma and CLL |
Median [range]: 69 [30–82], 43.5% |
BNT162b2, mRNA-1273 |
28D or 21D |
First Dose and Second Dose |
Median [range]: 24 [22–56], 43.5% |
First Dose: 23 |
1.07 |
5 |
Patients (n = 22) |
Second Dose: 23 |
Seronegative (n = 13) |
|
Seropositive (n = 9) |
|
|
|
Dose 2: |
|
Patients (n = 21) |
|
Seronegative (n = 9) |
|
Seropositive (n = 12) |
|
S.R-41% & 57% |
|
Fiorino et al., 2021, Italy, Prospective cohort |
Dose 2: |
MF |
Median [range]: 67 [31–85], 50% |
BNT162b2, mRNA-1273 |
3–4 W |
Second Dose |
NA |
40 |
≥30% |
7 |
Patients (n = 42) |
(n = 40) |
Seronegative (n = 10) |
S.R-100% |
Seropositive (n = 32) |
|
S.R-76% |
|
Gastinne et al., 2022, France, Prospective cohort |
Dose 2: |
lymphoma, leukemia |
Median [range]: 62 [21–79], 60% |
BNT162b2 |
28D |
Second Dose |
NA |
25 |
≥0.8 U/mL |
6 |
Patients (n = 20) |
|
Seronegative (n = 14) |
|
Seropositive (n = 6) |
|
S.R-30% |
|
Gavriatopoulou et al., 2021, Greece, Prospective cohort |
Dose 1: |
WM, CLL, NHL |
Median [IQR]: 75 [40–88], 48.3% |
BNT162b2, AZD1222 |
21D-3M |
First Dose |
NA |
114 |
≥30% = positive, ≥50% = clinically relevant inhibition) |
8 |
Patients (n = 58) |
(n = 232) |
Seronegative (n = 50) |
S.R-54% |
Seropositive (n = 8) |
|
S.R-14% |
|
Gavriatopoulou et al., 2021, Greece, Prospective cohort |
Dose 1: |
WM |
Median [IQR]: 73 [64–81], 43.4% |
BNT162b2, AZD1222 |
21D-3M |
First Dose and Second Dose |
Median [IQR]: 66 [62–82], 46.2% |
First Dose: 212 |
≥30% = positive, ≥50% = clinically relevant inhibition) |
8 |
Patients (n = 106) |
Second Dose: 212 |
Seronegative (n = 70) |
S.R-96.2% |
Seropositive (n = 36) |
|
|
|
Dose 2: |
|
Patients (n = 74) |
|
Seronegative (n = 29) |
|
Seropositive (n = 45) |
|
S.R-34% & 61% |
|
Ghione et al., 2021, USA, Prospective cohort |
Dose 2: |
lymphoma |
Median [range]: 70 [35–91], 52.3% |
BNT162b2, mRNA-1273 and Ad26.COV2.S |
28D or 21D |
Second Dose |
NA |
154 |
≥1.0 |
6 |
Patients (n = 86) |
(n = 154) |
Seronegative (n = 50) |
S.R-100% |
Seropositive (n = 36) |
|
S.R-42% |
|
Guglielmelli et al., 2021, Italy, Prospective cohort |
Dose 1: |
MF, ET, PV |
NA |
BNT162b2, AZD1222 |
28D or 21D |
First Dose |
NA |
14 |
≥15 AU/mL |
6 |
Patients (n = 30) |
(n = 14) |
Seronegative (n = 12) |
S.R-100% |
Seropositive (n = 18) |
|
S.R-60% |
|
Herishanu et al., 2021, Israel, Prospective cohort |
Dose 2: |
CLL |
Median [IQR]: 69.0 [63.0–73.7], 67.1% |
BNT162b2 |
21D |
Second Dose |
Median [IQR]: 68 [64–74.7] |
52 |
≥0.8 IU/mL = positive |
8 |
Patients (n = 52) |
(n = 52) |
Seronegative (n = 25) |
S.R-100% |
Seropositive (n = 27) |
|
S.R-52% |
|
Jurgens et al., 2021, USA, Prospective cohort |
Dose 2: |
Lymphoma and CLL |
Median [range]: 71 [24–90], 53.7% |
BNT162b2, mRNA-1273 |
28D or 21D |
Second Dose |
NA |
35 |
10000 |
5 |
Patients (n = 67) |
|
Seronegative (n = 36) |
|
Seropositive (n = 31) |
|
S.R-46% |
|
Lim et al., 2021, UK, Prospective cohort |
Dose 1: |
lymphoma |
Median [IQR]: 69 [57–74], 62.8% |
ChAdOx1, BNT162b2 |
10-12 W |
First Dose and Second Dose |
Median [IQR]: 45 [34–47], 33.3% |
150 |
Meso scale discovery >0.55 BAU/mL, Anti–SARS-CoV-2 RBD IgG >0.73 BAU/mL |
6 |
Patients (n = 59) |
(n = 150) |
Seronegative (n = 27) |
S.R-100% |
Seropositive (n = 32) |
|
|
|
Dose 2: |
|
Patients (n = 86) |
|
Seronegative (n = 25) |
|
Seropositive (n = 61) |
|
S.R-54% & 71% |
|
Mairhofer et al., 2021, Austria, Prospective cohort |
Dose 2: |
Cancer |
NA |
BNT162b2, mRNA-1273 |
28D or 21D |
Second Dose |
NA |
28 |
≥50 IU/mL |
7 |
Patients (n = 45) |
(n = 29) |
Seronegative (n = 19) |
S.R-96.6% |
Seropositive (n = 26) |
|
S.R-58% |
|
Malard et al., 2021, France, Retrospective cohort |
Dose 2: |
LM, MM |
Median [range]: 68.9 [21.5–91.7], 59.7% |
BNT162b2 |
28D |
Second Dose |
NA |
|
≥50 AU/mL = positive; ≥3100 = neutralization) |
9 |
Patients (n = 196) |
|
Seronegative (n = 105) |
|
Seropositive (n = 91) |
|
S.R-46% |
|
Marasco et al., 2022, Italy, Prospective cohort |
Dose 2: |
LM |
Median [range]: 56 [46–62], 56.3% |
BNT162b2, mRNA-1273 |
28D or 21D |
Second Dose |
Median [range]: 56 [46–62], 56.3% |
167 |
≥0.8 IU/mL |
9 |
Patients (n = 167) |
(n = 167) |
Seronegative (n = 60) |
S.R-100% |
Seropositive (n = 107) |
|
S.R-64% |
|
Marchesi et al., 2022, Italy, Prospective cohort |
Dose 2: |
MM |
NA |
BNT162b2 |
21D |
Second Dose |
NA |
28 |
≥15 U/m |
6 |
Patients (n = 49) |
(n = 28) |
Seronegative (n = 12) |
S.R-100% |
Seropositive (n = 37) |
|
S.R-76% |
|
McKenzie et al., 2021, UK, Prospective cohort |
Dose 2: |
HM |
Median [IQR]: 35 [27–48], 64.7% |
BNT162b2, mRNA-1273 |
70D |
Second Dose |
Median [IQR]: 66 [52.75–73], 69.2% |
22 |
antibody level ED50, nAb assay: IC50 |
5 |
Patients (n = 51) |
(n = 26) |
Seronegative (n = 29) |
S.R-88% |
Seropositive (n = 22) |
|
S.R-43% |
|
Monin et al., 2021, UK, Prospective cohort |
Dose 1: |
Hematological Cancer |
Median [IQR]: 73 [64.5–79.5], 52.3% |
BNT162b2 |
21D |
First Dose and Second Dose |
Median [IQR]: 40.5 [31.3–50], 52.9% |
First Dose: 32 |
≥70 EC50 = positive |
7 |
Patients (n = 44) |
(n = 34) |
Seronegative (n = 36) |
S.R-94% |
Seropositive (n = 8) |
Second Dose: 12 |
|
(n = 12) |
Dose 2: |
S.R-100% |
Patients (n = 5) |
|
Seronegative (n = 2) |
|
Seropositive (n = 3) |
|
S.R-18% & 60% |
|
Parry et al., 2022, UK, Prospective cohort |
Dose 2: |
B cell CLL |
Median [IQR]: 67 [60–72], 53% |
AZD1222, BNT162b2 |
3 W |
Second Dose |
Median [IQR]: 71 [64–77], 55.9% |
93 |
≥0.8 |
7 |
Patients (n = 500) |
(n = 93) |
Seronegative (n = 165) |
S.R-100% |
Seropositive (n = 335) |
|
S.R-67% |
|
Parry et al., 2021, UK, Prospective cohort |
Dose 1: |
CLL |
Median [IQR]: 69 [63–74], 54.7% |
AZD1222, BNT162b2 |
12 W and 3 W |
First Dose and Second Dose |
NA |
First Dose: 95 |
≥0.8 |
7 |
Patients (n = 86) |
Second Dose: 59 |
Seronegative (n = 57) |
(N = 95 & 59) |
Seropositive (n = 29) |
S.R-100% |
|
|
Dose 2: |
|
Patients (n = 12) |
|
Seronegative (n = 3) |
|
Seropositive (n = 9) |
|
S.R-34% & 75% |
|
Peeters et al., 2021, Belgium, Prospective multicohort |
Dose 2: |
Cancer |
Median [range]: 63 [25–79], 58.5% |
BNT162b2 |
21D |
Second Dose |
NA |
Second Dose: 40 |
≥5 IU/mL |
6 |
Patients (n = 41) |
(n = 40) |
Seronegative (n = 29) |
S.R-100% |
Seropositive (n = 12) |
|
S.R-29% |
|
Perry et al., 2021, Israel, Prospective cohort |
Dose 2: |
B-NHL |
Median [range]: 64 [20–92], 59.1% |
BNT162b2 |
21D |
Second Dose |
Median [range]: 66 [25–83], 44.6% |
65 |
≥0.8 IU/mL |
8 |
Patients (n = 149) |
S.R-98.5% |
Seronegative (n = 76) |
|
Seropositive (n = 73) |
|
S.R-49% |
|
Pimpinelli et al., 2021, Italy, Prospective cohort |
Dose 1: |
MM, MPM |
Median [range]: 73 [47–78] |
BNT162b2, mRNA-1273 |
21D |
First Dose and Second Dose |
Median [range]: 81 [79–87], 50% |
First Dose: 36 |
≥15 U/m |
9 |
Patients (n = 92) |
Median [range]: 70 [28–80], 53.3% |
Second Dose: 36 |
Seronegative (n = 57) |
|
n = 36 |
Seropositive (n = 35) |
|
S.R-100% |
|
|
|
Dose 2: |
|
|
Patients (n = 92) |
|
|
Seronegative (n = 15) |
|
|
Seropositive (n = 77) |
|
|
S.R-38% & 84% |
|
|
Rahav et al., 2021, Israel, Prospective cohort |
Dose 2: |
CLL, NHL, MM, and MDS |
Median [IQR]: 69 [61–74] |
BNT162b2 |
21D |
Second Dose |
NA |
269 |
≥1.1 |
9 |
Patients (n = 529) |
Median [IQR]: 66 [59–73] |
(n = 272) |
Seronegative (n = 175) |
Median [IQR]: 62 [49–70] |
S.R-98.9% |
Seropositive (n = 354) |
Median [IQR]: 73 [66–80], 58.8% |
|
S.R-67% |
|
Schiller-Salton et al., 2021, Israel, Prospective cohort |
Dose 2: |
MM |
Mean ± SD: 67.8 ± 9.9, 58.50% |
BNT162b2 |
30D |
Second Dose |
NA |
Second Dose: 360 |
≥150 AU/mL |
8 |
Patients (n = 176) |
|
Seronegative (n = 47) |
|
Seropositive (n = 129) |
|
S.R-73% |
|
Shem-Tov et al., 2022, Israel, Prospective cohort |
Dose 2: |
HSCT |
Mean ± SD: 58 ± 14.0, 63.20% |
BNT162b2, mRNA-1273 |
21D |
Second Dose |
Mean ± SD: 55.6 ± 14.2, 24.3% |
269 |
Cut point: >1.1 |
7 |
Patients (n = 152) |
(n = 272) |
Seronegative (n = 34) |
S.R-98.9% |
Seropositive (n = 118) |
|
S.R-78% |
|
Shen et al., 2021, Australia, Prospective cohort |
Dose 2: |
CLL |
Median [range]: 71.5 [22–94], 56.3% |
BNT162b2, mRNA-1273, AZD1222 |
2-4 W |
Second Dose |
NA |
25 |
≥50 AU/mL |
6 |
Patients (n = 160) |
|
Seronegative (n = 72) |
|
Seropositive (n = 88) |
|
S.R-55% |
|
Stampfer et al., 2021, USA, Retrospective cohort |
Dose 1: |
MM |
Median [range]: 68 [35–88], 59.4% |
BNT162b2, mRNA-1273 |
28D or 21D |
First Dose and Second Dose |
Median [range]: 61 [26–85] |
First Dose: 31 |
50-250 IU/mL partial response, >250 IU/mL |
8 |
Patients (n = 96) |
Second Dose: 31 |
Seronegative (n = 76) |
n-31 |
Seropositive (n = 20) |
|
|
S.R-100% |
Dose 2: |
|
Patients (n = 96) |
|
Seronegative (n = 32) |
|
Seropositive (n = 64) |
|
S.R-21% & 67% |
|
Terpos et al., 2021, Greece, Prospective cohort |
Dose 1: |
CLL, NHL, HL |
Mean ± SD: 64.6 ± 14.3, 50% |
BNT162b2 |
21D |
First Dose and Second Dose |
Mean ± SD: 69.8 ± 12.5, 44.9% |
First Dose: 152 |
GenScript (≥30% = positive, ≥30% = clinically relevant) |
6 |
Patients (n = 132) |
(n = 214) |
Seronegative (n = 103) |
S.R-71% |
Seropositive (n = 29) |
Second Dose: 214 |
|
(n = 214) |
Dose 2: |
S.R-98.1% |
Patients (n = 132) |
|
Seronegative (n = 65) |
|
Seropositive (n = 67) |
|
S.R-22% & 51% |
|
Terpos et al., 2021, Greece, Prospective cohort |
Dose 1: |
MM, SM, MGUS |
Median [IQR]: 74 [62–80], 54.7% |
BNT162b2, AZD1222 |
21D-3M |
First Dose and Second Dose |
NA |
First Dose: 145 |
GenScript (≥30% = positive, ≥30% = clinically relevant) |
8 |
Patients (n = 276) |
|
Seronegative (n = 159) |
(n = 225) |
Seropositive (n = 117) |
|
|
S.R-64.2% |
Dose 2: |
Second Dose: 204 |
Patients (n = 276) |
(n = 226) |
Seronegative (n = 80) |
S.R-90.3% |
Seropositive (n = 196) |
|
S.R-42% & 71% |
|
Terpos et al., 2021, Greece, Prospective cohort |
Dose 1: |
MM |
Mean ± SD: 81.68 ± 7.63, 60.40% |
BNT162b2 |
21D |
First Dose |
Mean ± SD: 81.56 ± 8.11, 54.8% |
57 |
GenScript (≥30% = positive, ≥30% = clinically relevant) |
8 |
Patients (n = 48) |
(n = 104) |
Seronegative (n = 36) |
S.R-54.8% |
Seropositive (n = 12) |
|
S.R-25% |
|